Diane Simeone to head translational oncology program at NCRC

Diane Simeone, M.D. will assume the directorship of the translational oncology program at NCRC.

Simeone is the Lazar J. Greenfield Endowed Professor of Surgery and professor of molecular and integrative physiology. She is also currently the director of the multidisciplinary pancreatic tumor program at the U-M Comprehensive Cancer Center.

Diane Simeone, M.D.

Simeone is both a dedicated pancreatic surgeon and an internationally recognized biomedical researcher, whose research is focused on understanding the molecular mechanisms regulating the development and progression of pancreatic cancer.

Being closely connected to the U-M Health System’s vision to create the future of health care through discovery, Simeone will lead a diverse program consisting of of a large number of research laboratories whose areas of expertise include basic molecular and cellular biological processes, novel preclinical models of cancer, the identification of new drugs that target cellular processes unique to the cancer cell and the translation of these discoveries into the clinic.

“Diane is an inspirational biomedical researcher with an unparalleled record of accomplishment in the area of pancreatic cancer biology and is one of our leading cancer surgeons,” said Colin Duckett, Ph.D., director of program development at NCRC.

“We’re thrilled that she has accepted this vital leadership role at NCRC. She will spearhead a highly motivated interdisciplinary team of investigators from many departments, schools and colleges within the university who are focused on the development of novel strategies to beat cancer.”

Simeone and her team plan to move their research programs to NCRC in early 2013.

“The focus of the translational oncology program at NCRC will be singular – how to treat cancer better,” Simeone said in a recent interview.

“To make this happen we will adopt a comprehensive approach: on one hand researching the disease from different angles by drawing on the vast and world class expertise of our basic scientists, clinicians and experimental therapeutics researchers, and on the other, focusing on drug development and commercialization processes in order to reach patients faster. I am tremendously excited to develop this vision at NCRC.”